Gastroesophageal Reflux Clinical Trial
Official title:
Effects of Non-nutritive Sucking on Gastroesophageal Reflux, Apneas and Bradycardias in Symptomatic Preterm Infants.
Gastro-esophageal reflux (GER) is a common condition among preterm infants, due to several
physiological promoting factors. To limit the potentially harmful widespread of
pharmacological treatment, a step-wise approach, which firstly applies conservative
strategies, is currently considered the best choice to manage GER in the preterm population.
Among the most common conservative strategies, postural measures seem to represent an
effective measure to reduce GER features in symptomatic preterm babies, whereas feed
thickening is almost ineffective. Non-nutritive sucking (NNS) is a care strategy largely
applied in the Neonatal Intensive Care Unit (NICU) settings. The act of swallowing is both
reported to trigger the onset of transient lower esophageal sphincter relaxations (TLESRs),
thereby eliciting to GER episodes, and to promote the esophageal clearance of refluxate.
Hence, a possible effect of NNS on GER features might be hypothesized.
This observational, prospective and explorative study primarily aims to explore the effect
of NNS, applied by means of a pacifier, on acid and non-acid GER features, evaluated in
symptomatic preterm infants (gestational age ≤32 weeks) undergoing a diagnostic combined pH
and multiple intraluminal impedance (pH-MII). The secondary aim of this study is to
evaluate, in the subgroup of patients with recurrent GER-related apneas, the effect of NNS
on cardiorespiratory events, defined as bradycardias and total, central, obstructive, mixed
apneas and detected by a simultaneous polysomnographic monitoring.
Due to several promoting factors related to the physiological immaturity of the
gastro-intestinal tract, gastro-esophageal reflux (GER) is a frequent condition among
preterm infants.
GER clinical presentation may vary within a wide range of symptoms, being vomiting,
regurgitations and cardiorespiratory events, such as apnoeas or bradycardia, the most common
in the preterm population. Particularly, apneic episodes are inversely related to the
gestational age (GA) and might be associated with such pathological events as hypoxia,
hypercapnia or pressure variability, which seem to negatively affect the long-term
neurological development of preterm babies.
Combined pH and multiple intraluminal impedance (pH-MII) is currently considered the best
choice for GER diagnosis in preterm infants. While pH monitoring is limited to the detection
of acid reflux, combined pH-MII effectively identifies both acid and non-acid GER, which is
predominant in preterm babies. Moreover, thanks to its multichannel probe, combined pH-MII
allows to evaluate the height reached by the refluxate within the esophageal lumen and to
distinguish retrograde fluid bolus movements (reflux) from the anterograde ones (swallows).
In the last decade, GER pharmacological treatment has increasingly widespread in NICUs. The
provision of anti-histamine2 (H2) blockers and proton pump inhibitors (PPI) in the preterm
population, however, might lead to such adverse effects as an increased incidence of
necrotizing enterocolitis and infections. Hence, to avoid a useless and potentially harmful
pharmacological overtreatment, a step-wise approach, firstly promoting conservative
strategies, is currently considered the most advisable choice for GER management in
symptomatic preterm infants.
Postural and dietetic interventions represent the most common conservative strategies and
their efficacy in improving GER symptoms and features has been largely investigated.
As we assessed in a previous pH-MII study, both prone and left-side positions were more
effective than the right-side or the supine ones to determine a significant improvement in
both acid and non-acid GER features.
Feed thickening is widely employed to reducing vomiting and regurgitations in symptomatic
term infants; with regard to the preterm population, however, little data is currently
available. We have previously investigated the efficacy of thickened fortified human milk on
preterm infants suffering from GER symptoms (frequent regurgitations, desaturations,
bradycardia), observing no benefits. Furthermore, standard human milk fortification itself
has been shown to increase GER frequency in preterm infants.
With regard to anti-regurgitation (AR) formulas, we have recently evaluated the
effectiveness of a specific AR formula, thickened with amylopectin and specifically tailored
for preterm infants' nutritional needs; the tested thickened formula effectively reduced the
number of acid GERs, but no difference was observed in the frequency of non-acid GERs and in
the mean esophageal acid exposure, which is known to be the main determinant for the
development of gastro-esophageal reflux disease (GERD). Thus, according to these preliminary
data, feed thickening seem to be almost ineffective in improving GER symptoms and features
in preterm infants.
Non-nutritive sucking (NNS) is part of the routine neonatal care, being widely applied in
NICU settings. NNS has been showed to positively influence gastric secretion, gut motility
and to improve the digestive process. NICU hospitalization and the need for respiratory
support, however, might delay the transition from tube feeding to full oral feeding, thereby
increasing the length of hospital stay and negatively affecting the mother-neonate
relationship. Over two decades ago, in their meta-analysis Schwartz et al. showed beneficial
effects of NNS in reducing time to attain full oral feeding as well as the length of
hospitalization. These results have been further confirmed in a recent review by Harding.
The role of NNS on GER, however, has not been yet clarified. It has been previously shown
that the swallowing enhances the occurrence of lower oesophageal sphincter relaxations,
which are known to represent a trigger stimulus for reflux episodes. On the other hand, the
act of swallowing appears to promote the esophageal clearance of refluxate; hence, a
possible influence of NNS on GER might be hypothesized. In a pH-metric study, performed by
Orenstein et al. on infants younger than 6 months, NNS seemed to have a worsening effect on
GER when applied in the prone posture, whereas in the seated position was associated with an
ameliorative outcome; this controversial result, however, cannot be extended to the preterm
population. To date, the efficacy of NNS by means of a pacifier on preterm infants
symptomatic for GER has been preliminary evaluated only by Zhao et al., reporting an
improvement of overall GER features (number of refluxes, reflux index, total time at pH<4)
and a faster time of gastric emptying in the NNS group. However, this study was performed by
pH monitoring, so that the effect of NNS on non-acid GER has not been evaluated yet.
Due to the buffering effect of milk feeding on gastric pH, and being the acidity of gastric
juice GA-dependent, non-acid GERs represent a major percentage (70%) of the overall reflux
episodes in the preterm population. Moreover, as we have recently observed, non-acid reflux
is the main responsible for the occurrence of GER-related apneas. Hence, a beneficial effect
on GER-related apneas and subsequent hypoxic episodes, potentially harmful for preterm
infants, could be supplied by conservative strategies effective in decreasing non-acid GERs
features.
The primary aim of this observational, prospective, exploratory study is to evaluate the
effect of NNS on GER pH-MII features in preterm infants (GA ≤32 weeks) symptomatic for GER
(i.e. suffering from frequent regurgitations, feeding difficulties, failure to thrive and/or
post-prandial desaturations) for which a 24-hour pH-MII monitoring for GER diagnostic
evaluation has been scheduled.
The secondary aim of this study is to assess, by means of a simultaneous non-invasive 6-hour
polysomnographic recording, the effect of NNS on total, central, obstructive, mixed apneas
and on cardiorespiratory events within the subgroup of patients with recurrent
desaturations.
Overall thirty preterm infants (GA ≤32 weeks) will be enrolled if suffering from
moderate/severe GER symptoms and if a diagnostic 24-hour pH-MII monitoring has been
scheduled to evaluate GER features, according to our clinical practice.
During the 24-h pH-MII monitoring each infant will receive eight meals, four of which will
be followed by NNS treatment with a pacifier. The sequence of NNS application will be
consecutively alternated in study participants. For each evaluation, a minimum of 2 hours of
NNS post-prandial treatment is required. The healthcare assistants (i.e. medical staff and
nurses) will inspect the correct application of NNS, recording the effective time of
pacifier usage and regularly checking the pacifier position in relation to the pH-MII probe
and polysomnographic flow sensor, to avoid possible interferences. Due to their immaturity,
the enrolled patients might show an ineffective sucking, potentially losing the pacifier. In
this case, the healthcare assistants will offer the pacifier to the babies up to a maximum
of four times for each postprandial period; measures to fix the pacifier will be avoided.
The pH-MII device in use for this study (Comfortec pH-MII Sandhill Scientific) is a
nasogastric probe with seven rings, composed by six dipolar impedance channels and one
antimony electrode responsible for pH detection and placed in the middle of the distal
impedance dipole. Due to these characteristics, pH-MII is able to measure the esophageal
height reached by refluxate and to identify the direction of esophageal bolus movements,
thereby distinguish between a retrograde flow (reflux) and an anti-retrograde flow
(swallow). Esophageal probe length will be determined using Strobel's formula: [baby length
(cm) x 0.252 + 5)] - 13%.
Impedance monitoring detects a GER episode (MII-GER) if there is a sequential drop in
impedance values to less than 50% of the baseline, starting distally and propagating
retrogradely to at least the next two more proximal measuring segments (about 4.5 cm above
the lower esophageal sphincter (LES)). A GER episode is then defined as acid or non-acid
according to its pH: the MII episodes with a pH lower than 4 are defined as acid MII-GERs,
whereas the MII episodes with a pH≥4 are defined as non-acid MII-GERs. GERs migration height
is the maximum distance from the LES reached by the esophageal refluxate. An acid GER
episode is recorded by pH monitoring as a pH drop to less than 4; to be detected by the pH
sensor, the pH drop has to last at least 5 s. The total percent time of esophageal exposure
to a pH <4 is named Reflux Index (RIpH).
Data from the pH-MII recording will be automatically acquired on a portable Sleuth Sandhill
Scientific system and then stored in a personal computer containing a specific software
(BioVIEW Analysis Sandhill Scientific, version 5.0.9). Data analysis will be performed by
the aforementioned software and confirmed by direct visual evaluation.
In the subgroup of patients with recurrent desaturations, a simultaneous non-invasive 6-hour
polysomnographic monitoring, comprehensive of two meals (one followed by NNS and the other
not), will be performed to evaluate a possible effect of NNS on apneic episodes (total,
central, obstructive, mixed) and cardiorespiratory events.
The polysomnographic device in use for this study (System Plus, Micromed, Mogliano Veneto,
Italy) measures the oral/nasal airflow by a flow transducer placed below the nostrils,
whereas abdominal movements are detected by a band placed around the abdomen which is
connected to a respiratory inductance plethysmography. Each oral/nasal flow cessation ≥5
seconds will be considered an apneic episode; apneas are then classified as central (CA:
absence of both oral/nasal flow and movements of the abdominal wall), obstructive (OA:
abdominal movements with an inadequate oral/nasal flow) and mixed (MA: components of both CA
and OA). Apneas included in periodic breathing patters will be ruled out from the analysis.
Systemic oxygen saturation is recorded by means of a pulse oximeter sensor, placed on the
infant's foot. Cardiorespiratory events will be characterized as hypoxic episodes, defined
as the occurrence of SatO2 <80%, and/or bradycardia, defined as pulse rate <100 bpm. The
polysomnographic recording is automatically acquired in a computer connected to the
polysomnographic device. The number of total apneas, CA, OA, MA and cardiorespiratory events
will be traced down and visually analyzed by the sub-investigators.
Statistical analysis will be performed by SPSS 20 (Statistical Package for the Social
Sciences, SPSS Inc., Chicago, IL, USA) for Windows. Differences between NNS and control
periods in terms of GER frequency and features, number of apneic and bradycardic episodes
will be tested by Wilcoxon Signed Ranks Test. The level of significance is set at 0.05.
;
Observational Model: Case-Only, Time Perspective: Prospective
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05561179 -
Hyaluronic Acid in Patients With Gastroesophageal Reflux Disease
|
N/A | |
Withdrawn |
NCT02213887 -
Study of the Effects of Pantoprazole on Levels of Prescribed Psychiatric Medications
|
Phase 4 | |
Completed |
NCT01946971 -
Lansoprazole in Preterm Infants With Gastroesophageal Reflux (GER)
|
Phase 1/Phase 2 | |
Recruiting |
NCT01825473 -
Study of Erythromycin in GER-Associated Apnea of the Newborn
|
N/A | |
Completed |
NCT00614536 -
Study of Changes in Reflux Symptoms and Reflux Finding Score According to Rabeprazole Treatment Period
|
Phase 4 | |
Completed |
NCT00373997 -
Esophageal and Laryngeal Tissue Changes in Patients Suspected of Having Laryngopharyngeal Reflux
|
Phase 4 | |
Completed |
NCT00365300 -
Study Evaluating the Efficacy and Safety of Pantoprazole in Infants With Symptomatic Gastroesophageal Reflux Disease (GERD)
|
Phase 3 | |
Completed |
NCT00284908 -
Dose-Effect of S-Tenatoprazole-Na(STU-Na) 30 mg, 60 mg, 90 mg and 120 mg in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT01167543 -
Relationship and Pathophysiology of Gastroesophageal Reflux and Dental/Periodontal Disease
|
N/A | |
Completed |
NCT00215787 -
Investigation of the Association Between Nasal Polyposis and Extraesophageal Reflux Disease
|
N/A | |
Completed |
NCT00291746 -
Validation of RDQ Questionnaire
|
Phase 4 | |
Completed |
NCT00567021 -
German PMS Trial (AWB) to Evaluate Therapy in Reflux Disease and NSAR-Symptoms
|
N/A | |
Completed |
NCT00141960 -
Famotidine in Subjects With Non-erosive Gastroesophageal Reflux Disease
|
Phase 2/Phase 3 | |
Completed |
NCT00226044 -
Rectal and Oral Omeprazole Treatment of Reflux Disease in Infants.
|
Phase 3 | |
Completed |
NCT01048840 -
Natural History of Gastroesophageal Reflux (GER) in Children < 12 Years of Age
|
||
Completed |
NCT00181805 -
Natural History of Gastroesophageal Reflux (GER) in Children and Adolescents
|
||
Terminated |
NCT01281553 -
A Study of Cisapride in Patients With Symptomatic Gastro-Oesophageal Reflux Disease
|
Phase 4 | |
Completed |
NCT05486169 -
Gastroesophageal Reflux Disease After Laparoscopic Sleeve Gastrectomy
|
N/A | |
Completed |
NCT04034017 -
Gastroesophageal Reflux Disease Among College Students
|
||
Terminated |
NCT03226054 -
Determining Risk Factors for Successful PPI Weaning
|
N/A |